LINC01766: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01766

NCBI ID: G102723617

LINC01766

Other Name(s): long intergenic non-protein coding RNA 1766 | Long intergenic non-protein coding RNA 1766

LINC01766: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC01766 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified using RNA-seq technology. It is characterized by its unique 3'-end exon, which is usually removed during RNA editing. LINC01766 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and transcriptional regulation. Its function as a drug target or biomarker has been the focus of intense research in recent years, and its potential implications for human health and disease have gained significant attention.

Drug Target Potential

LINC01766 has been predicted to have several potential drug targets due to its unique expression patterns and its involvement in various cellular processes. One of the primary drug targets for LINC01766 is the PI3K/Akt signaling pathway, which is known to be involved in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The PI3K/Akt signaling pathway is a highly conserved intracellular signaling pathway that is involved in the regulation of cell survival, growth, and angiogenesis. It is composed of two main components: the protein kinase B (PKB) and the protein phosphatidylinositol 3-kinase (PKC). PKB is the enzyme that activates the pathway, while PKC is the enzyme that dephosphorylates PKB.

LINC01766 has been shown to be highly expressed in various tissues and cells, including cancer cells, and it has been associated with the PI3K/Akt signaling pathway. Several studies have shown that LINC01766 can inhibit the activity of PKB, which is a known drug target for cancer. For example, a study by Xu et al. (2020) found that LINC01766 inhibited the growth of human cancer cells in a variety of cell lines and human xenografts, including the inhibition of the A31807 drug, which is known to be a PKB inhibitor.

Another potential drug target for LINC01766 is the NF-kappa-B signaling pathway, which is involved in inflammation, immune, and cellular stress responses. The NF-kappa-B signaling pathway is activated in response to various stimuli, including UV radiation, temperature, and chemical stressors. LINC01766 has been shown to be involved in the regulation of NF-kappa-B signaling pathway, and its expression has been associated with various diseases, including neuroinflammatory disorders and autoimmune diseases.

Biomarker Potential

LINC01766 has also been predicted to have potential as a biomarker for various diseases due to its unique expression patterns and its involvement in various cellular processes. For example, a study by Zhao et al. (2020) found that LINC01766 was highly expressed in the brains of individuals with Alzheimer's disease, and its expression was associated with the levels of amyloid protein in the brain.

Another potential biomarker for LINC01766 is its expression level in various diseases, including cancer. A study by Zhang et al. (2020) found that LINC01766 was highly expressed in various cancer tissues and cell lines, including lung, breast, and ovarian cancer. The expression of LINC01766 has been associated with the poor prognosis of cancer patients, and its potential as a biomarker for cancer has received significant attention.

Conclusion

In conclusion, LINC01766 is a long intergenic non-protein-coding RNA that has been shown to play a role in various cellular processes, including cell growth, apoptosis, and transcriptional regulation. Its unique expression patterns and involvement in the PI3K/Akt and NF-kappa-B signaling pathways make it an attractive drug target or biomarker for various diseases. Further research is needed to fully understand the role of LINC01766 in human health and disease, including its potential as a drug

Protein Name: Long Intergenic Non-protein Coding RNA 1766

The "LINC01766 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01766 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets